Home Healthcare IT Cardiometabolic Disease Market Size, Top Share & Analysis Report to 2032

Cardiometabolic Disease Market

Cardiometabolic Disease Market Size, Share & Trends Analysis Report By Treatment (Angiotensin-converting Enzyme (ace) Inhibitors, Diuretics, Glucophage, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI55905DR
Study Period 2020-2032 CAGR 4.3%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX.X billion
Forecast Year 2032 Forecast Year Market Size USD XX.X billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

Cardiometabolic disease is a broad word that refers to a group of problems that raise the risk of cardiovascular disease (CVD) and metabolic disorders, precisely type 2 diabetes. This category of illnesses has common risk factors and frequently coexists in individuals, increasing the risk of morbidity and mortality. Obesity, insulin resistance, dyslipidemia (abnormal lipid levels in the blood), and hypertension (high blood pressure) are the primary causes of cardiometabolic illnesses. High consumption of fast food due to changing lifestyles, which would lead to increased obesity rates, and increased use of biomarkers for diagnostic and risk assessment procedures are the major factors influencing the cardiometabolic disease market growth.

Furthermore, the growing number of patients adopting pharmaceuticals and therapeutics due to the proliferation of digital modes of drug delivery, as well as innovations and advancements in drug delivery technologies in the healthcare industry, will drive the expansion of the cardiometabolic disease market. Furthermore, increased adoption of AI technology in the healthcare business, resulting in improved support services, will be a market driver, accelerating growth.

Market Dynamics

Global Cardiometabolic Disease Market Drivers

Growing Aging Population

The world population is witnessing a demographic change with a growing share of elderly folks. Aging is related to an increased risk of acquiring cardiometabolic disorders due to variables such as decreasing metabolic efficiency, hormonal changes, and lifestyle factors developed over the years. According to the World Health Organization (WHO), the global population aged 60 years and older is predicted to more than double by 2050, reaching over 2.1 billion. This demographic transition has important implications for healthcare systems, as older persons are more prone to chronic disorders, particularly cardiometabolic diseases. Cardiovascular diseases, a subgroup of cardiometabolic diseases, grow increasingly frequent with age. Conditions such as atherosclerosis, hypertension, and heart failure are widely reported in the aged population, contributing to the overall burden of cardiometabolic disorders. 

According to the American College of Cardiology (ACC), coronary heart disease (CHD) is frequent in the elderly, and the prevalence of CHD increases with age; 14.2% of persons aged 45 years and older reported having coronary heart disease (CHD), a or a stroke, or both. 9.6% of adults aged 45 to 64 years reported being diagnosed with CHD, a stroke, or both, compared with 21.7% of individuals aged 65 years and older. The aging population offers fiscal issues to healthcare systems. A study published in the Journal of the American Geriatrics Society emphasized the increasing healthcare expenses associated with the aging population, with a significant percentage due to the management of chronic disorders, including cardiometabolic diseases. Thus, the cardiometabolic disease market trend will evolve with the expanding aging population.

Global Cardiometabolic Disease Market Restraints

High Cost

Cardiometabolic disorders (CMD) are a primary cause of death globally, with high healthcare expenses and a lower quality of life. Cardiovascular medications, which frequently comprise a significant portion of the cardiometabolic illness market, are subjected to rigorous testing. For example, a pharmaceutical company developing a new antihypertensive treatment must invest extensively in clinical trials to demonstrate its efficacy in lowering blood pressure and its safety profile. Heart disease treatment alone costs an average of USD 229 billion each year. In 2018, heart disease cost the United States an estimated USD 203.3 billion in annual income, while stroke cost USD 63.6 billion.

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have severe procedures for approving new pharmaceuticals. Companies must expend enormous resources to ensure their products meet regulatory requirements. Drug development has a high attrition rate, with many prospective medicines failing to market. The expenses of failing a medication candidate, particularly in the late stages of development, can be significant. This covers the money spent on the unsuccessful candidate and the opportunity cost of resources that could have been used for other potential ventures.

Global Cardiometabolic Disease Market Opportunity

Rising Disease Burden

Cardiometabolic disorders, such as obesity, type 2 diabetes, hypertension, and dyslipidemia, have seen a significant rise in prevalence worldwide. According to the Globe Health Organization (WHO), non-communicable diseases (NCDs), which include cardiovascular disease and diabetes, are the leading cause of death in the globe, accounting for 71% of all fatalities. Between 1999 and 2018, the prevalence of cardiometabolic multimorbidity in US adults grew from 9.4% to 14.4%. The prevalence of cardiometabolic illnesses varies from 4.3% for diabetes to 37.3% for dyslipidemia. More precisely, the global prevalence of diabetes has been continuously rising. According to the International Diabetes Federation (IDF), 10.5% of persons aged 20 to 79 have diabetes. The IDF predicts that by 2045, one in every eight adults, or approximately 783 million people, will have diabetes. Type 2 diabetes accounts for the vast majority of diabetes cases and is closely connected to lifestyle variables.

Furthermore, obesity, a significant contributor to cardiometabolic illnesses, is a global health issue. The World Obesity Federation estimates that 2.7 billion persons worldwide will be overweight or obese by 2025. This stresses the importance of interventions addressing the underlying causes and the accompanying health hazards. Unhealthy lifestyle choices, such as sedentary behavior and poor eating habits, have a substantial role in the growth of cardiometabolic disorders. Lifestyle-related risk factors provide an opportunity for treatments centered on prevention and health promotion.

Regional Analysis

The global cardiometabolic disease market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global cardiometabolic disease market shareholder and is estimated to grow at a CAGR of 4.6% over the forecast period. Rising healthcare product demand and developing economies are responsible for this region's growth. North America, which includes the United States and Canada, is a significant market for cardiometabolic disease management. According to the CDC, diabetes affects 38.4 million individuals in the United States, accounting for 11.6% of the population. 29.7 million people have been diagnosed with diabetes. The high prevalence of diabetes highlights the need for drugs, technologies, and healthcare services to control this cardiometabolic illness.

Furthermore, North America leads the way in technological advances in healthcare. Mobile applications for remote patient monitoring, wearable devices, and telehealth platforms are examples of digital health technologies that help to manage cardiometabolic disorders holistically. The United States boasts a robust biotechnology industry and prestigious research universities. In 2020, the United States placed first in new pharmaceuticals and medical devices that received regulatory approval.

Europe is anticipated to exhibit a CAGR of 4.4% over the forecast period. The European region has experienced tremendous growth owing to a well-developed healthcare system, a sizable patient population with cardiovascular diseases, and a high adoption rate of modern treatment alternatives. An emphasis on research and development in cardiovascular medicine also helps to drive market expansion. Furthermore, obesity is a prominent factor driving the market in the region. According to the World Obesity Atlas 2023, obesity is anticipated to rise 7% among women and 13% among men in Europe between 2020 and 2035. Furthermore, according to a WHO estimate from 2023, one out of every three children in Europe is overweight. Obesity is a severe public health concern that raises the risk of chronic diseases such as hypertension, diabetes, and, ultimately, cardiometabolic disease.

However, several European countries have national health systems that provide inhabitants with total healthcare coverage. These systems help people manage cardiometabolic disorders by making drugs, diagnostic tests, and specialist care more accessible.

The Asia-Pacific cardiometabolic disease market is predicted to develop at the quickest CAGR over the forecast period, according to cardiometabolic disease market insights. Asia-Pacific held a significant market share during the forecast period due to the region's quickly increasing medical infrastructures, severe government regulations on public healthcare, and notable manufacturers' adoption of various market expansion techniques. Furthermore, China's cardiometabolic disease market had the highest market share, while India's Cardiometabolic Disease market was the fastest expanding in the Asia-Pacific region. 

Additionally, diabetes is particularly prevalent in China and India, which adds to the demand for cardiometabolic disease care services. According to the International Diabetes Foundation, China and India have the world's highest and second-highest diabetes rates, respectively. In 2021, China had 140.9 million people with diabetes, whereas India had 74.2 million. Furthermore, antihypertensive medicines such as ACE inhibitors and calcium channel blockers are frequently given to manage hypertension throughout the Asia-Pacific area. Hypertension is a significant health concern in Asia-Pacific, affecting more than 35% of adults. The prevalence of hypertension in the region is 5-47% in males and 7-38% in women. Given the high prevalence of hypertension in countries such as China and Japan, these drugs have a substantial impact on the cardiometabolic disease market.

Report Scope

Report Metric Details
By Treatment
  1. Angiotensin-converting Enzyme (ace) Inhibitors
  2. Diuretics
  3. Glucophage
  4. Others
By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
  4. Others
Company Profiles Cardax Inc. Novartis AG Novo Nordisk A/S Eli Lilly and Company Bayer AG Allergan Boehringer Ingelheim International GmbH AstraZeneca
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global cardiometabolic disease market is segmented based on treatment, distribution channel, and region.

The market is further segmented by treatment into Angiotensin-converting Enzyme (ace) Inhibitors and Diuretics.

Angiotensin-converting Enzyme (ACE) Inhibitors account for the largest share of the market. The angiotensin-converting enzyme (ACE) inhibitors sector dominates the market since they are used to treat hypertension and heart failure. ACE inhibitors are a type of drug often used to treat hypertension and heart failure. They work by inhibiting the activity of the angiotensin-converting enzyme, a critical component of the renin-angiotensin-aldosterone system. ACE medications inhibit this enzyme, which reduces the formation of angiotensin II, a hormone that causes blood vessels to contract. This vasodilation lowers blood pressure, improves cardiac function, and decreases the stress on the heart. ACE inhibitors can also help diabetic patients by slowing the progression of diabetic nephropathy, a common kidney problem.

Diuretics, sometimes known as water pills, enhance urine production, allowing the body to remove excess sodium and water. Diuretics are frequently used in the treatment of cardiometabolic illnesses to control hypertension and reduce fluid retention in conditions such as heart failure. Diuretics help lower blood pressure by decreasing the volume of blood in circulation. This category includes thiazide diuretics, loop diuretics, and potassium-sparing diuretics, each with its mechanism of action and indications.

By Distribution channels, the market is further bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital Pharmacies are a significant contributor to the market. The Hospital Pharmacies category produced the most significant revenue. The growing number of hospitals and the increased need for medications to treat CMDs will drive segmental growth. Hospital pharmacies are essential to the healthcare system, dispensing pharmaceuticals on the hospital grounds. Patients being treated for acute diseases, such as severe hypertension or heart failure, frequently acquire their prescribed medications directly from hospital pharmacies. Hospital pharmacists ensure that patients with cardiometabolic disorders can access the needed medications, particularly during inpatient care or immediately after discharge. They also work with healthcare experts to track patients' responses to treatment.

Chain pharmacies, independent pharmacies, and local drugstores are all examples of retail pharmacies found in communities. These pharmacies provide convenient locations for patients to get their prescribed drugs for long-term therapy of cardiometabolic diseases. Retail pharmacists offer advice on drug adherence, possible adverse effects, and lifestyle changes. Patients can fill their prescriptions, obtain over-the-counter drugs, and consult with pharmacists about maintaining their cardiometabolic health. Retail pharmacies play an important role in providing care outside of the hospital.

Market Size By Treatment

Recent Developments

  • January 2024- In a Phase III trial for newly diagnosed chronic myeloid leukemia patients, Novartis Scemblix® outperformed standard-of-care TKIs regarding primary molecular response (MMR) rates.
  • January 2024- Novo Nordisk collaborated with Omega Therapeutics and Cellarity to develop innovative treatments for cardiometabolic disorders.
  • January 2024- Eli Lilly and Company launched LillyDirect™, a digital healthcare experience for US patients suffering from obesity, migraine, and diabetes. 
  • June 2023- The FDA approved VASCEPA capsules, the first prescription therapy composed entirely of icosapent ethyl, a form of eicosapentaenoic acid.

Top Key Players

Cardax Inc. Novartis AG Novo Nordisk A/S Eli Lilly and Company Bayer AG Allergan Boehringer Ingelheim International GmbH AstraZeneca Others

Frequently Asked Questions (FAQs)

Which market sector is expected to dominate over the forecast period?
Hospital pharmacies market sector is expected to dominate over the forecast period.
Growing aging population is the major growth factor of the cardiometabolic disease market.
North America region has the highest growth rate in the cardiometabolic disease market.
Key verticals adopting cardiometabolic disease include: - Cardax Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim International GmbH, AstraZeneca.

We are featured on :